Page results
-
UCLH provides an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
We provide an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia. We provide an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia.
-
UCLH is considered a centre of excellence in the management of patients with Hodgkin’s and non-Hodgkin’s lymphoma.
-
The bone marrow transplant and haematopoietic stem cell transplant service at UCLH is the largest in Europe and provides a full range of transplant services.
-
UCLH is a designated Haemophilia Centre providing a 24/7 service for patients, including those needing treatment with blood products and clotting factor medications.
-
Thalassaemia is a group of inherited blood conditions where the part of the blood known as haemoglobin is abnormal.
-
Patient information for patients who are having a bone marrow biopsy.
-
This page is intended for women with a cyst or abscess of the Bartholin’s gland. It provides information on the condition and the treatment options available in our hospital.
File results
-
FOI/2022/0169 - Strategic workforce plan for recruitment and retention of Allied Health Professions
-
FOI/2022/0171 - Consultant-led Referral to Treatment (RTT), outpatients and Patient Initiated Follow-up (PIFU)
-
FOI/2022/0172 - Contraceptive pill data
-
FOI/2022/0174 - Clinical systems for bed management, diagnostic reporting, discharge letters, and integration platform systems
-
FOI/2022/0177 - Assessment and treatment unit for mental health and learning disabilities
-
FOI/2022/0186 - Gender neutral toilets at the Trust
-
FOI/2022/0187 - Intra-operative cell salvage procedures
-
FOI/2022/0189 - Drug treatments for Revolade, Nplate, Doptelet, and Tavlesse
-
FOI/2022/0190 - Spend on private healthcare providers for staff
-
FOI/2022/0192 - Drug treatment for Melanoma patients